Navigation Links
Neura Therapeutik and AIT Laboratories Partner to Promote Pain Products
Date:9/6/2012

PRINCETON, N.J. and INDIANAPOLIS, Sept. 6, 2012 /PRNewswire/ -- Neura Therapeutik and AIT Laboratories have formed a strategic partnership to explore the possibility of co-promoting current and future analgesic products to pain specialty physicians. Under the terms of the agreement, Neura would support AIT's national sales force with its established commercial drug and development infrastructure.

In a 2011 report issued by Research and Markets, it is estimated that the U.S. market for pain management therapeutics will generate more than $40 billion annually and is expected to grow to $60 billion by 2015. This market includes treatments for a wide range of conditions including postoperative pain, cancer, arthritis, migraines and back pain. "Entering into this strategic partnership allows AIT to complement our existing laboratory testing and is consistent with AIT's position as a healthcare company offering healthcare practitioners options to help them treat patients with chronic pain," said AIT President and CEO Ron Thieme, Ph.D. AIT Laboratories is a national healthcare company specializing in compliance monitoring, forensics and clinical testing.

Neura Therapeutik is a pain specialty company led by a management team with years of experience in the analgesic market that has successfully launched blockbuster drugs such as Duragesic® and Vicodin ES®. "We are very excited about the collaboration with AIT and are confident that the efforts of their sales force will strengthen the position of our analgesic product portfolio," said Neura Therapeutik CEO John LaLota. "The addition of AIT's sales force, together with the efforts of our institutional sales force, will allow us to effectively educate pain treating physicians about the scientific value and patient benefits offered by our products and those of our co-promotion partners."

Chronic pain affects an estimated 116 million adults in the U.S. -- more than the number affected by heart disease, diabetes, and cancer combined, according to a report by the Institute of Medicine. "AIT has worked with healthcare practitioners treating chronic pain for many years and we know the challenges they sometimes face in finding relief for their patients," said Thieme. "The sophisticated data we provide from our laboratory reports coupled with information about new analgesics in the market, will give healthcare practitioners additional avenues to effectively treat their patients and improve patient outcomes."

About Neura Therapeutik:
Neura Therapeutik LLC (Neura) is a pain specialty company focused on the commercialization of innovative analgesics that address unmet needs in the marketplace. Neura is divided into two strategic business units:

  • Neura Labs, LLC – Focused on the in-licensing and launch of pharmaceutical assets where Neura's development and commercial experience can be leveraged to provide value enrichment through optimal clinical development and commercial advancement.
  • Neura Group, LLC – Focused on providing an array of commercial services and management oversight that will optimize the value of market ready/currently marketed assets.
  • Please visit neuratherapeutik.com for more information.
  • About AIT Laboratories
    AIT Laboratories, headquartered in Indianapolis, Ind., is a national healthcare company that specializes in compliance testing, forensic toxicology drug testing and clinical laboratory testing. The employee-owned company is recognized nationwide for superior customer service and quality in testing. To learn more about AIT, visit AITLABS.com; follow us on Twitter and like us on Facebook.Media Contacts:Raquel Bahamonde

    Greg GirondaAIT Laboratories

    Neura Therapeutik LLC 317-308-0064

    609-256-1942rbahamonde@aitlabs.com

    girondag@neuratherapeutik.com


    '/>"/>
    SOURCE AIT Laboratories
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Neuralstem Announces Exercise Of Entire Over-Allotment Option By Aegis Capital Corp.
    2. Phosphagenics Appoints Neura Therapeutik as US Strategic Commercial Advisors
    3. Neura Therapeutik Forms Business Units to Pursue Analgesic Market Opportunities
    4. Seventeenth Patient Dosed in Neuralstem ALS Stem Cell Trial
    5. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
    6. Sixteenth Patient Dosed In Neuralstem ALS Stem Cell Trial
    7. Neuralstem Updates ALS Stem Cell Trial Progress
    8. Millennium Laboratories Angela Huskey Named Industry Pain Educator of the Year by American Society of Pain Educators
    9. Nelson Laboratories to Present Latest FDA Trends at MEDevice Forum San Diego
    10. SureGene and PGXL Laboratories launch the SureGene Test for Antipsychotic and Antidepressant Response (STA2R)
    11. Millennium Laboratories Announces Landmark Pharmacogenetics Clinical Outcomes Study
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016 ... appointment of Dr. Edward Futcher to ... Director, effective June 23, 2016.Dr. Futcher was also ... and Governance Committees.  As a non-executive member of ... expertise and strategic counsel to VolitionRx in connection ...
    (Date:6/23/2016)... 23, 2016  MedSource announced today that it ... software solution of choice.  This latest decision demonstrates ... to their clients by offering a state-of-the-art electronic ... establishes nowEDC as the EDC platform of choice ... clients.  "nowEDC has long been a preferred EDC ...
    (Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his ... David Geffen School of Medicine at UCLA. He trained in Internal Medicine at Scripps ... in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to ...
    (Date:6/24/2016)... Los Angeles, CA (PRWEB) , ... June 24, 2016 , ... ... plastic surgery procedures that most people are unfamiliar with. The article goes on to ... known procedures, but also many of these less common operations such as calf and ...
    (Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
    (Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
    (Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... client, The Grove Investment Group (TGIG), has initiated cultivation and processing operations at ... Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of a complete ...
    Breaking Medicine News(10 mins):